The Cost of Implementing and Sustaining the Massachusetts Model

Why It Matters

The analysis provides health systems with a clear, per‑patient cost benchmark comparable to existing MOUD reimbursements, facilitating informed budgeting and scaling decisions for primary‑care addiction services.

Key Takeaways

• Implementation cost averages $238,888 per clinic; $3,185 per patient year 1.
• Variable costs represent ~67% of year‑1 expenses, driven by NCM labor.
• Annual sustainment cost drops slightly to $229,676 per clinic, $3,062 per patient.
• NCMs devote ~1,968 hours yearly, over seven times PCP time.
• Per‑patient cost aligns with typical MOUD reimbursement, aiding payer negotiations.

Pulse Analysis

The United States continues to grapple with an opioid crisis that generated over $960 billion in economic losses in 2023, with primary care identified as a pivotal venue for expanding medication‑assisted treatment. The Massachusetts Model leverages a full‑time nurse care manager to streamline buprenorphine and extended‑release naltrexone delivery, allowing primary‑care physicians to focus on broader clinical duties. By embedding care coordination, screening, and follow‑up within the clinic workflow, the model addresses longstanding barriers such as staffing constraints and fragmented services, positioning primary care as a sustainable front line for opioid use disorder (OUD) management.

The recent microcosting analysis quantifies the financial footprint of this approach. Fixed start‑up expenditures, including training and supplies, total just over $9,000 per clinic, while recurring space and technical assistance costs amount to $70,000 annually. However, the lion’s share—approximately 67% of year‑one costs and 69% thereafter—stems from variable labor, especially the NCM’s 1,968 hours of patient‑focused work each year. At $3,062 per patient annually, the MA Model’s cost aligns with typical reimbursement rates for OUD medication programs, suggesting that payers could cover the intervention without imposing additional financial strain on providers.

From a strategic perspective, the predominance of variable costs renders the model’s marginal expansion cost‑linear, simplifying budget projections for health systems contemplating scale‑up. Sensitivity analyses reveal that patient caseload and provider mix dramatically influence total outlays, highlighting the importance of accurate demand forecasting. The study’s accompanying customizable budget impact tool empowers clinics to tailor cost estimates to local labor rates and patient volumes, facilitating data‑driven decisions. As policymakers seek cost‑effective solutions to curb opioid‑related morbidity, the MA Model’s transparent economics and demonstrated labor efficiencies make it a compelling candidate for broader adoption and further outcome‑based evaluation.